Patrick Burnett, an insider at Arcutis Biotherapeutics, is set to sell 1,691 shares of common stock on 12/31/2024. The transaction, classified as an open market or private sale, will be executed at a price of $14.00 per share, totaling $23,674 in value.Following this planned disposition, Burnett will retain direct ownership of 126,978 shares of Arcutis Biotherapeutics common stock. The transaction is currently in progress and scheduled for the last day of 2024, indicating a future planned sale.This insider transaction provides insight into executive stock movements at Arcutis Biotherapeutics, a biopharmaceutical company. While the sale represents a reduction in Burnett's holdings, it's important to note that he will maintain a significant stake in the company post-transaction.

Patrick Burnett, an insider at Arcutis Biotherapeutics, is set to sell 1,691 shares of common stock on 12/31/2024. The transaction, classified as an open market or private sale, will be executed at a price of $14.00 per share, totaling $23,674 in value.Following this planned disposition, Burnett will retain direct ownership of 126,978 shares of Arcutis Biotherapeutics common stock. The transaction is currently in progress and scheduled for the last day of 2024, indicating a future planned sale.This insider transaction provides insight into executive stock movements at Arcutis Biotherapeutics, a biopharmaceutical company. While the sale represents a reduction in Burnett's holdings, it's important to note that he will maintain a significant stake in the company post-transaction.